Profile data is unavailable for this security.
About the company
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
- Revenue in USD (TTM)0.00
- Net income in USD-40.94m
- Incorporated2008
- Employees6.00
- LocationAnnovis Bio Inc101 LINDENWOOD DRIVE, SUITE 225MALVERN 19355United StatesUSA
- Phone+1 (484) 875-3192
- Fax+1 (610) 727-4001
- Websitehttps://www.annovisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genelux Corp | 8.00k | -27.66m | 88.07m | 23.00 | -- | 2.63 | -- | 11,008.18 | -0.9537 | -0.9537 | 0.0003 | 0.9703 | 0.0002 | -- | -- | 347.83 | -74.41 | -- | -92.15 | -- | -- | -- | -345,750.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 90.11m | 10.00 | -- | 32.22 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -104.16m | 91.35m | 154.00 | -- | 0.5243 | -- | -- | -2.17 | -2.17 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -55.16 | -33.76 | -60.53 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Generation Bio Co | 18.58m | -145.47m | 91.51m | 174.00 | -- | 0.8756 | -- | 4.92 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Annovis Bio Inc | 0.00 | -40.94m | 91.75m | 6.00 | -- | 12.51 | -- | -- | -3.76 | -3.76 | 0.00 | 0.5318 | 0.00 | -- | -- | 0.00 | -333.05 | -106.31 | -523.91 | -124.71 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | -121.90 | -- | -- | -- |
| Hillevax Inc | 0.00 | -150.28m | 92.64m | 90.00 | -- | 0.4993 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 93.05m | 300.00 | -- | -- | -- | 1.15 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Inotiv Inc | 501.06m | -99.22m | 93.37m | 1.96k | -- | 0.5127 | -- | 0.1863 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 93.41m | 18.00 | -- | 0.6148 | -- | 141.75 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 4.47m | 94.33m | 15.00 | 23.43 | 0.6014 | 20.48 | -- | 0.0999 | 0.0999 | 0.00 | 3.89 | 0.00 | -- | -- | 0.00 | 2.22 | -- | 2.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 8.72m | -20.11m | 95.16m | 75.00 | -- | 1.44 | -- | 10.91 | -0.1096 | -0.1096 | 0.0474 | 0.3505 | 0.086 | -- | 20.83 | 116,253.30 | -19.77 | -19.53 | -22.80 | -22.59 | 95.00 | 89.13 | -229.91 | -370.88 | -- | -- | 0.0021 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Assembly Biosciences Inc | 28.33m | -40.80m | 95.60m | 65.00 | -- | 3.68 | -- | 3.37 | -7.54 | -7.54 | 5.14 | 4.09 | 0.373 | -- | -- | 435,784.60 | -53.73 | -39.69 | -79.14 | -44.03 | -- | -- | -144.05 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Regulus Therapeutics Inc | 0.00 | -41.63m | 96.29m | 32.00 | -- | 1.11 | -- | -- | -1.08 | -1.08 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -63.31 | -53.74 | -71.29 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 97.05m | 127.00 | -- | 1.82 | -- | 19.41 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -64.82m | 97.57m | 54.00 | -- | 1.99 | -- | -- | -1.93 | -1.93 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.23 | -80.06 | -106.79 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Data as of Nov 26 2024. Currency figures normalised to Annovis Bio Inc's reporting currency: US Dollar USD
7.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 378.32k | 2.90% |
| Citadel Securities LLCas of 30 Sep 2024 | 102.69k | 0.79% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 99.75k | 0.76% |
| Geode Capital Management LLCas of 30 Sep 2024 | 99.11k | 0.76% |
| Kieger AGas of 31 Mar 2023 | 53.33k | 0.41% |
| Group One Trading LLCas of 30 Sep 2024 | 52.77k | 0.40% |
| Quest Partners LLCas of 30 Sep 2024 | 46.00k | 0.35% |
| Wescott Financial Advisory Group LLCas of 30 Sep 2024 | 41.61k | 0.32% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 36.04k | 0.28% |
| Sterling Investment Advisors Ltd.as of 30 Sep 2024 | 34.47k | 0.26% |
More ▼
Data from 31 Mar 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
